QYUNS-B (02509) Announces Monthly Return for February 2026

Bulletin Express03-05

Qyuns Therapeutics Co., Ltd. reported that, as of 28 February 2026, its authorized share capital remained at 227.07 million shares with a par value of RMB 1, totaling RMB 227.07 million. Issued shares (excluding treasury shares) decreased from 224.87 million to 224.57 million, while treasury shares increased from 2.20 million to 2.50 million. Overall, the total number of shares remained 227.07 million.

According to the announcement, 307,000 shares were repurchased on 2, 3, 4, and 6 February 2026 at prices ranging from HKD 20.12 to HKD 20.24. These repurchased shares were held as treasury shares, and the applicable public float requirement continued to be met. No other movements in issued shares, convertible securities, or share options were recorded for the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment